fatty liver

In MASLD, aspirin use alone correlated with lower all-cause mortality and fewer liver-related events over roughly three years in multi-institutional data, without establishing causality. Signals appear most decision-relevant when cardiovascular indications ...

In metabolic dysfunction-associated steatotic liver disease (MASLD), use of aspirin alone was associated with differences in risks of all-cause mortality and liver-related events over three years in a multi-institutional analysis. Findings are observational...

In metabolic dysfunction-associated steatotic liver disease (MASLD), aspirin exposure was associated with lower all-cause mortality and fewer liver-related events over a three-year horizon in a multi-institutional cohort. Signals align with antiplatelet and...

In metabolic dysfunction-associated steatotic liver disease, aspirin monotherapy was evaluated over three years for associations with all-cause mortality and liver-related events across multiple institutions. Adjusted time-to-event analyses examined effect ...